VCV000143968.17 - ClinVar

NM_024675.4(PALB2):c.2834+1G>T

Germline

Classification

The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.

(8)

Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.

Pathogenic/Likely pathogenic

criteria provided, multiple submitters, no conflicts

Somatic

No data submitted for somatic clinical impact

Somatic

No data submitted for oncogenicity

Variant Details

Identifiers

NM_024675.4(PALB2):c.2834+1G>T

Variation ID: 143968 Accession: VCV000143968.17

Type and length

single nucleotide variant, 1 bp

Location

Cytogenetic: 16p12.2 16: 23624008 (GRCh38) [ NCBI UCSC ] 16: 23635329 (GRCh37) [ NCBI UCSC ]

Timeline in ClinVar

	First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.	Last submission Help The date of the most recent submission for each type of classification for this variant.	Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline	Aug 24, 2014	Oct 8, 2024	Sep 24, 2024

HGVS

Nucleotide	Protein	Molecular consequence
NM_024675.4:c.2834+1G>T MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.		splice donor
NM_001407296.1:c.2774+1G>T		splice donor
NM_001407297.1:c.2762+1G>T		splice donor
NM_001407298.1:c.2672+1G>T		splice donor
NM_001407299.1:c.2834+1G>T		splice donor
NM_001407300.1:c.2834+1G>T		splice donor
NM_001407301.1:c.2834+1G>T		splice donor
NM_001407302.1:c.2672+1G>T		splice donor
NM_001407304.1:c.1949+1G>T		splice donor
NM_001407305.1:c.1949+1G>T		splice donor
NM_001407306.1:c.1949+1G>T		splice donor
NM_001407307.1:c.1787+1G>T		splice donor
NM_001407308.1:c.1949+1G>T		splice donor
NM_001407309.1:c.1949+1G>T		splice donor
NM_001407310.1:c.1949+1G>T		splice donor
NM_001407311.1:c.1949+1G>T		splice donor
NM_001407312.1:c.1046+1G>T		splice donor
NM_001407313.1:c.1046+1G>T		splice donor
NM_001407314.1:c.368+1G>T		splice donor
NC_000016.10:g.23624008C>A
NC_000016.9:g.23635329C>A
NG_007406.1:g.22350G>T
LRG_308:g.22350G>T
LRG_308t1:c.2834+1G>T

... more HGVS ... less HGVS

Protein change

Other names

Canonical SPDI

NC_000016.10:23624007:C:A

Functional consequence Help The effect of the variant on RNA or protein function, based on experimental evidence from submitters.

Global minor allele frequency (GMAF) Help The global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.

Allele frequency Help The frequency of the allele represented by this VCV record.

Links

ClinGen: CA294560 dbSNP: rs587776419 VarSome

Genes

Gene	OMIM	ClinGen Gene Dosage Sensitivity Curation		Variation Viewer Help Links to Variation Viewer, a genome browser to view variation data from NCBI databases.	Related variants
Gene	OMIM	HI score Help The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team.	TS score Help The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team.		Within gene Help The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants.	All Help The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene.
PALB2		-	-	GRCh38 GRCh37	5913	5955

Conditions - Germline

Condition Help The condition for this variant-condition (RCV) record in ClinVar.	Classification Help The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions)	Review status Help The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status.	Last evaluated Help The most recent date that a submitter evaluated this variant for the condition.	Variation/condition record Help The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page.
not provided	Likely pathogenic (2)	criteria provided, single submitter	Sep 24, 2024	RCV000133481.6
Familial cancer of breast	Pathogenic/Likely pathogenic (4)	criteria provided, multiple submitters, no conflicts	Mar 30, 2023	RCV000411304.10
Hereditary cancer-predisposing syndrome	Likely pathogenic (1)	criteria provided, single submitter	Jul 20, 2023	RCV000567638.5
Familial cancer of breast Fanconi anemia complementation group N Pancreatic cancer, susceptibility to, 3	Pathogenic (1)	criteria provided, single submitter	Oct 31, 2018	RCV000763377.3

Submissions - Germline

Classification Help The submitted germline classification for each SCV record. (Last evaluated)	Review status Help Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria)	Condition Help The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant.	Submitter Help The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar.	More information Help This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter.
Likely pathogenic (Jul 29, 2016)	criteria provided, single submitter (Counsyl Autosomal Dominant Disease Classification criteria (2015)) Method: clinical testing	Familial cancer of breast Affected status: unknown Allele origin: unknown	Counsyl Accession: SCV000488978.2 First in ClinVar: Jan 06, 2017 Last updated: Dec 24, 2022	Publications: PubMed (1) PubMed: 25099575
Likely pathogenic (Jul 20, 2023)	criteria provided, single submitter (Ambry Variant Classification Scheme 2023) Method: clinical testing	Hereditary cancer-predisposing syndrome Affected status: unknown Allele origin: germline	Ambry Genetics Accession: SCV000670660.6 First in ClinVar: Jan 01, 2018 Last updated: May 01, 2024	Publications: PubMed (1) PubMed: 25099575 Comment: The c.2834+1G>T intronic variant results from a G to T substitution one nucleotide after coding exon 8 of the PALB2 gene. This alteration has previously … (more) The c.2834+1G>T intronic variant results from a G to T substitution one nucleotide after coding exon 8 of the PALB2 gene. This alteration has previously been reported in one high-risk family with breast cancer (Antoniou AC et al. N. Engl. J. Med. 2014 Aug;371(6):497-506). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site; however, direct evidence is insufficient at this time (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. (less)
Pathogenic (Oct 31, 2018)	criteria provided, single submitter (ACMG Guidelines, 2015) Method: clinical testing	Familial cancer of breast Fanconi anemia complementation group N Pancreatic cancer, susceptibility to, 3 Affected status: unknown Allele origin: unknown	Fulgent Genetics, Fulgent Genetics Accession: SCV000894074.1 First in ClinVar: Mar 31, 2019 Last updated: Mar 31, 2019	Publications: PubMed (1) PubMed: 25741868 pmc: 4544753 pmc: 4544753 DOI: 10.1038/gim.2015.30 DOI: 10.1038/gim.2015.30
Likely pathogenic (Mar 30, 2023)	criteria provided, single submitter (Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)) Method: clinical testing	Familial cancer of breast Affected status: unknown Allele origin: unknown	Myriad Genetics, Inc. Accession: SCV004019217.1 First in ClinVar: Jul 29, 2023 Last updated: Jul 29, 2023	Comment: This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either … (more) This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. (less)
Pathogenic (Jun 13, 2020)	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015)) Method: clinical testing	Familial cancer of breast Affected status: unknown Allele origin: germline	Labcorp Genetics (formerly Invitae), Labcorp Accession: SCV000633380.4 First in ClinVar: Dec 26, 2017 Last updated: Feb 28, 2024	Publications: PubMed (5) PubMed: 16199547‚ 17200668‚ 24136930‚ 25099575‚ 26681312 Comment: Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction … (more) Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PALB2 are known to be pathogenic (PMID: 17200668, 24136930, 25099575). Disruption of this splice site has been observed in individuals affected with breast and/or ovarian cancer (PMID:25099575, 26681312, Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 143968). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 8 of the PALB2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. (less)
Likely pathogenic (Sep 24, 2024)	criteria provided, single submitter (GeneDx Variant Classification Process June 2021) Method: clinical testing	Not Provided Affected status: yes Allele origin: germline	GeneDx Accession: SCV000322191.8 First in ClinVar: Oct 09, 2016 Last updated: Oct 08, 2024	Comment: Canonical splice site variant demonstrated to result in a null allele in a gene for which loss of function is a known mechanism of disease … (more) Canonical splice site variant demonstrated to result in a null allele in a gene for which loss of function is a known mechanism of disease (PMID: 30890586); Observed in an individual with a personal and/or family history of breast and/or ovarian cancer (PMID: 25099575); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30890586, 25099575) (less)
pathogenic (-)	no assertion criteria provided Method: not provided	not provided Affected status: not provided Allele origin: germline	SNPedia Accession: SCV000188555.1 First in ClinVar: Aug 24, 2014 Last updated: Aug 24, 2014	Comment: Converted during submission to Pathogenic.
Pathogenic (May 13, 2019)	no assertion criteria provided Method: curation	Familial cancer of breast Affected status: yes Allele origin: germline	Leiden Open Variation Database Accession: SCV001193295.1 First in ClinVar: Apr 06, 2020 Last updated: Apr 06, 2020	Publications: PubMed (1) PubMed: 25099575 Comment: Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitter to LOVD: Marc Tischkowitz.

Comment:

The c.2834+1G>T intronic variant results from a G to T substitution one nucleotide after coding exon 8 of the PALB2 gene. This alteration has previously been reported in one high-risk family with breast cancer (Antoniou AC et al. N. Engl. J. Med. 2014 Aug;371(6):497-506). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site; however, direct evidence is insufficient at this time (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic.

Comment:

This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.

Comment:

Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PALB2 are known to be pathogenic (PMID: 17200668, 24136930, 25099575). Disruption of this splice site has been observed in individuals affected with breast and/or ovarian cancer (PMID:25099575, 26681312, Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 143968). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 8 of the PALB2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product.

Comment:

Canonical splice site variant demonstrated to result in a null allele in a gene for which loss of function is a known mechanism of disease (PMID: 30890586); Observed in an individual with a personal and/or family history of breast and/or ovarian cancer (PMID: 25099575); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30890586, 25099575)

Germline Functional Evidence

There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar.

Comment:

Citations for germline classification of this variant

Title	Author	Journal	Year	Link
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.	Susswein LR	Genetics in medicine : official journal of the American College of Medical Genetics	2016	PMID: 26681312
Breast-cancer risk in families with mutations in PALB2.	Antoniou AC	The New England journal of medicine	2014	PMID: 25099575
The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.	Janatova M	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology	2013	PMID: 24136930
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.	Rahman N	Nature genetics	2007	PMID: 17200668
Splicing in action: assessing disease causing sequence changes.	Baralle D	Journal of medical genetics	2005	PMID: 16199547

Text-mined citations for rs587776419 ...

These citations are identified by LitVar using the rs number, so they may include citations for more than one variant at this location. Please review the LitVar results carefully for your variant of interest.

Record last updated Oct 08, 2024

ClinVar Genomic variation as it relates to human health

NM_024675.4(PALB2):c.2834+1G>T

Variant Details

Genes

Conditions - Germline

Submissions - Germline

Germline Functional Evidence

Citations for germline classification of this variant

Text-mined citations for rs587776419 ...